What we tried to do with the development of Oikos Fusion was really lean into the nutrition science to understand what nutrients people taking a GLP-1 drug would be most likely be deficient in due to their lower caloric or energy intake, and really understand from a nutrition perspective, how we could uniquely support them, she said
1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing epidemic associated with metabolic disease ( Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including liraglutide, exenatide, semaglutide, beinaglutide, and dulaglutide, are commonly used in clinical practice to manage blood sugar and body weight
You can achieve sustainable results without invasive procedures or extreme dieting
Retatrutide does not hold MHRA marketing authorisation and is not licensed for use in the UK outside of regulated clinical trials
While compounded semaglutide may offer cost savings, it is important to weigh the potential risks and unknowns associated with compounded medications
